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The reactions between equimolar amounts of CuX2 (X = NO3 and CF3SO3) and two aromatic nitrogen-
containing heterocycles differing in the position of nitrogen atoms, 1,7- and 4,7-phenanthroline (1,7-
and 4,7-phen), were performed in ethanol/methanol at room temperature. When CuX2 salts were mixed 
with 4,7-phen, two copper(II) complexes, [Cu(NO3)2(4,7-Hphen)2](NO3)2 (1) and [Cu(CF3SO3)(4,7-
phen)2(H2O)2]CF3SO3 (2), were formed. On the other hand, in the reaction of CuX2 salts with 1,7-phen, 
only 1,7-HphenNO3 (3a/b) and 1,7-HphenCF3SO3 (4) were obtained as the ﬁnal products. The obtained 
products 1–4 were characterized by spectroscopic and X-ray diffraction techniques. In the copper(II) 
complexes 1 and 2, the coordination geometry around the Cu(II) ion is distorted octahedral and square 
pyramidal, respectively. The antimicrobial potential of the copper(II) complexes 1 and 2 and correspond-
ing compounds used for their synthesis were assessed against four different bacterial species and Candida 
albicans, displaying moderate growth inhibiting activity. The cytotoxic properties of the investigated 
complexes were also evaluated against the normal human lung ﬁbroblast cell line (MRC-5) indicating 
moderate, yet more pronounced cytotoxicity than antimicrobial properties.
1. Introduction
Copper is an essential element for almost all aerobic organisms
and is found in both animals and plants in different metalloen-
zymes, such as superoxide dismutase, cytochrome c oxidase, ceru-
loplasmin, tyrosinase and metallothioneins [1]. Under
physiological conditions, copper exists in two redox states, cuprous
(Cu+) and cupric (Cu2+), coordinated to proteins, while free copper
ions participate in the Fenton reaction leading to the formation of
reactive oxygen species [2]. As a soft Lewis acid, the Cu(I) ion tends
to interact with soft sulfur- and phosphorus-donor atoms mostly
forming complexes of tetrahedral geometry, although complexes
with nitrogen- and oxygen-donors are also reported [3]. The Cu
(II) ion is an intermediate Lewis acid and commonly forms com-
plexes with nitrogen- and oxygen-donors, whereby coordination
numbers 4, 5 and 6 are predominating. The ability of copper to
cycle between two oxidation states determines its biological func-
tion as a cofactor in enzymes catalyzing different redox reactions,
such as the oxidation of catechols, superoxide, ascorbate, as well
as iron [3,4]. Consequently, copper-containing metalloenzymes
support wide range of pharmacologically important processes
including mitochondrial oxidative phosphorylation, neurotrans-
mitter biosynthesis, antioxidant protection, pigment formation,
central nervous system development, connective tissue formation,
iron metabolism and copper transport [5–10].
Besides its essentiality, copper has been used as a potent
antimicrobial agent for the treatment of wounds and sterilization
of water throughout the history of civilization [11,12]. It was found
that surfaces containing 55–70% copper are efﬁcient against
several bacteria, such as Escherichia coli, Enterococcus faecalis,
Staphylococcus aureus, against the fungus Candida albicans, as well
as against inﬂuenza viruses and the human immunodeﬁciency
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virus (HIV) [13]. Between 2008 and 2011, the Environmental Pro-
tection Agency (EPA) registered more than 300 copper-based alloys
as antimicrobial agents that are effective against the microorgan-
isms responsible for the life-threatening infections, which was part
of the initiative for the manufacture of antimicrobial copper-based
surfaces in veterinary and healthcare settings [14]. There are dif-
ferent factors, which have an inﬂuence on the antimicrobial prop-
erties of copper: temperature and humidity, wet or dry application,
concentration, type of contact and form of copper [12]. Due to the
fact that simple inorganic salts of copper are usually toxic, a large
number of copper(II) complexes have been synthesized and evalu-
ated for their antimicrobial activities [15]. One of the advantages in
the administration of copper in a form of a complex is the selective
delivery of copper ions to the diseased tissues as well as the mod-
iﬁcation of pharmacokinetics and/or pharmacodynamics due to the
ligands [15]. Various copper(II) complexes with different ligands
showed considerable antibacterial and antifungal activities
[16–21]. Very recently, ﬁve copper(II) complexes with aromatic
nitrogen-containing heterocycles (N-heterocycles), e.g. pyrimidine,
pyrazine, quinazoline and phthalazine, were synthesized and eval-
uated for their activity against three clinically important patho-
gens, namely Pseudomonas aeruginosa, Staphylococcus aureus and
Candida albicans [22]. The obtained results showed that none of
the studied copper(II) complexes manifested signiﬁcant growth
inhibiting activity against the investigated strains. Nevertheless,
these complexes were able to inhibit bacterial quorum sensing
(QS) through the modulation of the level of signaling molecules
that are part of QS system [22]. This ﬁnding was very important
in view of the development of novel therapeutic agents that atten-
uate virulence rather than microbial growth, thus offering a lower
risk of resistance development. A considerable effect has been put
into designing copper complexes as anticancer agents as well, uti-
lizing the fact that the altered metabolism of cancer cells induces a
differential response towards endogenous metal ions in compar-
ison to healthy cells [23].
Although 1,7-phenanthroline (1,7-phen) and 4,7-phenanthro-
line (4,7-phen) showed no signiﬁcant biological activity, these N-
heterocycles were utilized for the synthesis of metal complexes
showing remarkable biological features [24–26]. Silver(I) com-
plexes with these ligands exhibited potent antifungal activity and
a good toxicological proﬁle in the zebraﬁsh model [24,25], while
mononuclear gold(III) complexes, [AuCl3(1,7-phen)] and
[AuCl3(4,7-phen)] had a markedly higher anti-angiogenic potential
than that of clinically relevant drugs, auranoﬁn and sunitinib [26].
Considering this, in the present study, we have decided to perform
reactions between these two N-heterocycles and Cu(II) ions. The
reactions between CuX2 salts (X = NO3 and CF3SO3) and 4,7-phen
lead to the formation of copper(II) complexes, [Cu(NO3)2(4,7-
Hphen)2](NO3)2 (1) and [Cu(CF3SO3)(4,7-phen)2(H2O)2]CF3SO3 (2).
However, in the reactions of 1,7-phen with these two copper(II)
salts, only 1,7-HphenNO3 (3a/b) and 1,7-HphenCF3SO3 (4) products
were obtained. The ﬁnal products of these reactions 1–4were char-
acterized by spectroscopy and X-ray crystallography. In vitro
antimicrobial and cytotoxic properties of copper(II) complexes 1
and 2 were evaluated against a panel of microbial strains and
healthy human lung ﬁbroblast cell line (MRC-5).
2. Experimental
2.1. Materials and methods
The copper(II) salts (Cu(NO3)23H2O and Cu(CF3SO3)2), 1,7-
phenanthroline (1,7-phen), 4,7-phenanthroline (4,7-phen),
ethanol, methanol, acetonitrile, dimethyl sulfoxide (DMSO) and
deuterated dimethyl sulfoxide (DMSO-d6) were obtained from
Sigma-Aldrich. All chemicals were of reagent-grade quality or
higher and used without further puriﬁcation.
The elemental analyses of the obtained compounds 1–4 for car-
bon, hydrogen and nitrogen were performed by the Microanalyti-
cal Laboratory, Faculty of Chemistry, University of Belgrade. The
IR spectra were recorded as KBr pellets on a Perkin Elmer Spectrum
100 spectrometer over the wavenumber range of 4000–450 cm1.
The UV–Vis spectra were recorded on a Shimadzu double-beam
spectrophotometer after dissolving the corresponding compound
in DMSO and after 24 and 48 h standing at room temperature over
the wavelength range of 900–200 nm. The concentration of the
solutions used for these measurements was 1102 M (1 and 2)
and 1103 M (3a/b and 4). The 1H and 13C NMR spectra of com-
pounds 3a/b and 4were recorded at room temperature on a Varian
Gemini 2000 spectrometer (1H at 200 MHz, 13C at 50 MHz). 5.0 mg
of each compound was dissolved in 0.6 mL of DMSO-d6 and trans-
ferred into a 5 mm NMR tube. Chemical shifts, d, are reported in
ppm (parts per million) and scalar couplings, J, are reported in
Hertz. Chemical shifts were calibrated relative to those of the
solvent.
2.2. Synthesis of copper(II) complexes 1 and 2
Copper(II) complexes with 4,7-phenanthroline, [Cu(NO3)2(4,7-
Hphen)2](NO3)2 (1) and [Cu(CF3SO3)(4,7-phen)2(H2O)2]CF3SO3 (2)
were synthesized according to the modiﬁed procedure for the
preparation of copper(II) complexes with aromatic N-heterocycles
[22]. The solution of 0.5 mmol of CuX2 salt (120.8 mg of Cu(NO3)2-
3H2O for 1 and 180.8 mg of Cu(CF3SO3)2 for 2) in 5.0 mL of ethanol
was added slowly under stirring to the solution containing an
equimolar amount of 4,7-phen (90.1 mg) in 5.0 mL of ethanol.
The reaction mixture was stirred at room temperature for 3–4 h.
Complex 1 crystallized from the mother ethanol solution after its
cooling in the refrigerator for three days, while those of complex
2 were obtained after recrystallization of the solid product precip-
itated from the reaction mixture in 10.0 mL of acetonitrile. The
blue crystals of 1 and green crystals of 2 suitable for single-crystal
X-ray crystallography were ﬁltered off and dried at ambient tem-
perature. Yield (calculated on the basis of 4,7-phen): 99.4 mg
(59%) for 1 and 127.0 mg (67%) for 2.
Anal. Calc. for 1 (C24H18CuN8O12; MW = 674.00): C, 42.77; H,
2.69; N, 16.63. Found: C, 42.64; H, 2.73; N, 16.58%. IR (KBr, m,
cm1): 3065w, 2931w (m(CarAH)), 1632m, 1597m, 1560w, 1500s
(m(Car@Car) and m(Car@N)), 1385s, 1356s, 1324s, 1280vs (mas(NO3)),
1242 m (m(CAN)), 828m, 634 m (c(CarAH)). UV–Vis (DMSO, kmax,
nm): 839.0 (e = 50.4 M1 cm1).
Anal. Calc. for 2 (C26H20CuF6N4O8S2; MW = 758.12): C, 41.19; H,
2.66; N, 7.39. Found: C, 41.05; H, 2.69; N, 7.42%. IR (KBr, m, cm1):
3407br (m(OAH)), 3080w, 3015w, 2903w (m(CarAH)), 1629w,
1604w, 1505m, 1454w, 1445w (m(Car@Car) and m(Car@N)),
1289vs, 1241vs, 1229s (mas(SO3)), 1225s (ms(CF3)), 1164s, 1154s
(mas(CF3)), 1026vs (ms(SO3)), 835m, 639s (c(CarAH)). UV–Vis (DMSO,
kmax, nm): 839.0 (e = 43.2 M1 cm1).
2.3. Synthesis of 3a/b and 4
The solution of CuX2 salt (0.5 mmol, 120.8 mg of Cu(NO3)23H2O
for 3a/b and 180.8 mg of Cu(CF3SO3)2 for 4) in 5.0 mL of ethanol (3a
and 4) or methanol (3b) was mixed with the solution of an
equimolar amount of 1,7-phen (90.1 mg) in 5.0 mL of ethanol (3a
and 4) or methanol (3b). After addition of 1,7-phen, a solution
changed color from blue to green, and no formation of metallic
copper was observed. The reaction mixture was stirred at room
temperature for 3–4 h and then left at room temperature to slowly
evaporate. Crystals of compounds 3a/b were obtained from the
mother solution, while those of compound 4 were obtained after
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J = 3.8 Hz, H2 and H8, isochronous), 9.65 ppm (d, J = 3.4 Hz, H6).
13C NMR (50 MHz, DMSO-d6): d = 122.68 (C10), 123.30 (C4),
125.27 (C4a), 126.83 (C10a), 129.59 (C3), 131.57 (C9), 133.55
(C6), 135.93 (C5), 143.94 (C1a), 147.63 (C6a), 149.50 (C2),
154.92 ppm (C8). IR (KBr, m, cm1): 3053w, 2923w (m(CarAH)),
1622m, 1596w, 1556w, 1434m (m(Car@Car) and m(Car@N)), 1384s
(mas(NO3)), 840m, 778m (c(CarAH)). UV–Vis (DMSO, kmax, nm):
268.0 (e = 2.0105 M1 cm1).
Anal. Calc. for 3b (C12H9N3O3; MW = 243.22): C, 59.26; H, 3.73;
N, 17.28. Found: C, 58.96; H, 3.70; N, 17.20%. The spectroscopic
data are the same as those for 3a.
Anal. Calc. for 4 (C13H9F3N2O3S; MW = 330.28): C, 47.27; H,
2.75; N, 14.53. Found: C, 46.95; H, 2.62; N, 14.27%. 1H NMR
(200 MHz, DMSO-d6): d = 4.12 (s, broad, NH), 7.85 (dd, J = 8.1,
4.4 Hz, H4), 7.98 (m, H10), 8.12 (d, J = 8.8 Hz, H3), 8.34 (d,
J = 9.1 Hz, H9), 8.62 (dd, J = 8.1, 1.7 Hz, H5), 9.15 (dd, J = 4.4,
1.7 Hz, H2), 9.17 (m, H8), 9.72 ppm (dd, J = 8.4 Hz, H6). 13C NMR
(50 MHz, DMSO-d6): d = 122.85 (C10), 123.41 (C4), 126.39 (C4a),
127.61 (C10a), 128.76 (C3), 131.06 (C9), 134.46 (C6), 136.61 (C5),
146.51 (C1a), 149.31 (C6a), 150.31 (C2), 152.70 ppm (C8). IR
(KBr, m, cm1): 3077w, 2931w (m(CarAH)), 1638m, 1626m,
1598m, 1556m, 1500m, 1454m, 1429w (m(Car@Car) and m(Car@N)),
1289vs, 1252vs (mas(SO3)), 1219vs (ms(CF3)), 1160vs (mas(CF3)),
1030vs (ms(SO3)), 857m, 640s (c(CarAH)). UV–Vis (DMSO, kmax,
nm): 268.0 (e = 2.3105 M1 cm1).
2.4. Crystallographic data collection and reﬁnement of the structures
Crystal data and details of the structure determinations are
listed in Table 1. A suitable crystal was selected, and the crystal
was mounted on a mylar loop in oil on a STOE IPDS 2 diffractome-
ter. The crystals were kept at 200(2) K for 1, 250(2) for 2 and 3a/b,
and 298(2) K for 4 during data collection. Using OLEX2 [27], the
structure was solved with the SHELXT [28] structure solution pro-
gram using Intrinsic Phasing and reﬁned with the SHELXL [29] reﬁne-
ment package using Least Squares minimization. Hydrogen
positions on aromatic rings were reﬁned with riding coordinates
with a ﬁxed Uiso (1.2 times), pyridium H was reﬁned with riding
coordinates and stretchable bond (Uiso 1.2), and all H positions
on water molecules were reﬁned with restraints (OAH 0.86(2),
Uiso 1.5). In case of complex 2, 91 restraints have been used with
oxygen atoms from water molecules deﬁned with a similar Uiso;
rigid body restraints were used on F- and O-atoms of the different
ﬂuorosulfonate groups and the site of occupation factors (s.o.f.) of
the ﬂuorosulfonate anions were reﬁned independently for each
group (O5, O6, O7 0.544(19); O11, O12, O13 0.913(4); O14, O15,
O16 0.776(4)). Diamond [30] program was used to prepare
drawings.
2.5. Antimicrobial studies
Test organisms for the antimicrobial assays were obtained from
the National Collection of Type Cultures (NCTC) and the American
T C lt C ll ti (ATCC) Th i l d d t G iti
trations of antifungal agents for yeasts) for C. albicans. The tested
compounds were dissolved in DMSO at 50 mg/mL. The highest
concentration used was 400 mM. The inoculums were 105 colony
forming units, cfu/mL, for bacteria and 104 cfu/mL for Candida
spp. The MIC value was recorded as the lowest concentration that
inhibited the growth after 24 h at 37 C.
2.6. In vitro cytotoxicity assay
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay [31]. The assay
was carried out using a monolayer (1  104 cells per well) of
human lung ﬁbroblast cell line (MRC-5) after 48 h of treatment
with compounds at concentrations ranging from 4 to 400 mM.
The MRC-5 cell line was maintained in RPMI 1640 medium (Ros-
well Park Memorial Institute medium), supplemented with
100 lg/mL streptomycin, 100 U/mL penicillin and 10% (v/v) fetal
bovine serum (FBS) (all from Sigma, Munich, Germany) as a mono-
layer and grown in humidiﬁed atmosphere of 95% air and 5% CO2 at
37 C. The extent of MTT reduction was measured spectrophoto-
metrically at 540 nm using a Tecan Inﬁnite 200 Pro multiplate
reader (Tecan Group Ltd., Männedorf, Switzerland), and the cell
survival was expressed as percentage of the control (untreated
cells). The percentage of viability values were plotted against the
log of concentration and a sigmoidal dose response curve was cal-
culated by non-linear regression analysis, using the Graphpad
Prism software, version 5.0 for Windows (Graphpad Software, CA,
USA). Cytotoxicity is expressed as the concentration of the com-
pound inhibiting growth by 50% (IC50).
3. Results and discussion
3.1. Different coordination abilities of 1,7- and 4,7-phen in the reaction
with Cu(II)
Two aromatic N-heterocycles, 1,7- and 4,7-phenanthroline (1,7-
and 4,7-phen) were used as ligands for the complexation to Cu(II)
ion (Scheme 1a and b). When the reactions were performed by
mixing equimolar amounts of CuX2 salts (X = NO3 and CF3SO3)
and 4,7-phen in ethanol as solvent at room temperature, the [Cu
(NO3)2(4,7-Hphen)2](NO3)2 (1) and [Cu(CF3SO3)(4,7-phen)2(H2O)2]
CF3SO3 (2) complexes were obtained as ﬁnal products (Scheme 1a).
On the other hand, in the reactions of these two Cu(II) salts with
1,7-phen under the same experimental conditions, only 1,7-
HphenNO3 (3a) and 1,7-HphenCF3SO3 (4) were isolated as reaction
products (Scheme 1b). Furthermore, in the reaction between
equimolar amounts of Cu(NO3)2 and 1,7-phen in methanol as the
solvent, the product 1,7-HphenNO3 (3b), which is a conformational
polymorph of 3a (vide infra), was obtained.
3.1.1. Description of the single crystal structures
The molecular structures of the copper(II) complexes 1 and 2
ith th t ll hi b i h d i t d i
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In complex 1, the Cu(II) ion is located at an inversion center and
has a distorted octahedral environment (Fig. 1 and Table 2). The Cu
(II) ion is coordinated by two nitrate anions bidentately and two
protonated 4,7-Hphen+ ligands which act in a monodentate fash-
ion. The average CuAN(4,7-phen) and CuAO(nitrate) bond dis-
tances compare well to those in the previously characterized
copper(II) complexes containing the 4,7-phenanthroline moiety
[32–35] and/or other aromatic N-heterocycles [22]. Uncoordinated
nitrogen atoms (N2) in both 4,7-phen ligands of 1 are protonated
and act as donors in hydrogen bonding with oxygen atoms of
nitrate counter-ions (Table 3). Contrary to the complex 1, in the
previously characterized [CuX2(4,7-phen)2] complexes (X = Cl,
Br and NO3), the Cu(II) ion has square planar geometry and is
coordinated by two 4,7-phen ligands and two X anions [32]. How-
ever, in the latter complexes, no protonation of the uncoordinated
nitrogen atoms was observed [32]. The protonation of nitrogen
Table 1
Details of the crystal structure determinations of 1–4.
1 2 3a 3b 4
Empirical formula C24H18CuN8O12 C26H20CuF6N4O8S2 C12H9N3O3 C12H9N3O3 C13H9F3N2O3S
CCDC number 1918878 1918879 1918880 1918881 1918882
Formula weight (g/mol) 674.00 758.12 243.22 243.22 330.28
Crystal system, space group triclinic, Pı triclinic, Pı monoclinic, C2/c monoclinic, P21/n triclinic, Pı
a (Å) 5.7292(4) 12.1353(7) 25.807(4) 12.5360(17) 6.2066(9)
b (Å) 6.9657(4) 13.9034(9) 3.7004(5) 6.7791(6) 10.0237(16)
c (Å) 16.9586(11) 19.1860(12) 24.199(3) 13.3532(18) 12.1087(17)
a () 88.620(5) 69.443(5) 100.201(12)
b () 87.931(5) 85.859(5) 115.780(9) 112.306(10) 104.259(11)
c () 69.129(5) 70.392(5) 102.899(12)
V (Å3) 631.92(7) 2851.4(3) 2080.9(5) 1049.9(2) 689.88(19)
F000 343 1532 1008 504 336
Z 1 2 8 4 2
X-radiation, k/Å Mo Ka 0.71073 Mo Ka 0.71073 Mo Ka 0.71073 Mo Ka 0.71073 Mo Ka 0.71073
Data collect. T (K) 200(2) 250(2) 250(2) 250(2) 298(2)
Calculated density (Mg/m3) 1.771 1.766 1.553 1.539 1.590
Absorption coefﬁcient (mm1) 0.952 1.010 0.115 0.114 0.284
Crystal size (mm3) 0.110  0.083  0.060 0.64  0.26  0.05 0.54  0.21  0.05 0.48  0.19  0.05 0.47  0.2  0.03
2h range () 2.4 to 50.4 3.3 to 53.8 3.5 to 52.9 3.8 to 52.5 3.6 to 52.5
Index ranges h, k, l 6 . . . 6, 8 . . . 8, 20
. . . 20
15 . . . 15, 17. . . 17,
24 . . . 24
31 . . . 31, 4 . . . 4,
30 . . . 30
15 . . . 15, 8 . . . 8,
16 . . . 16
7 . . . 7, 12 . . . 12,
15 . . . 15
No. of collected and independent
reﬂections
8217, 2248 43913, 12 144 9348, 2114 11820, 2113 8320, 2770
Rint 0.0567 0.0959 0.0863 0.0873 0.0706
Data/restraints/parameters 2248/0/206 12144/ 91 /925 2114/0 /168 2113/0/166 2770/0/203
Goodness-on-ﬁt on F2 1.008 1.014 1.082 0.985 0.977
Final R indices [I  2r(I)] 0.0386, 0.0869 0.0487, 0.1052 0.0741, 0.1234 0.0648, 0.1498 0.0521, 0.0995
Final R indices (all data) 0.0551, 0.0928 0.0880, 0.1233 0.1919, 0.1707 0.1646, 0.2000 0.1898, 0.1394
Difference density: max, min (e/Å3) 0.382, 0.460 0.75, 0.54 0.22, 0.20 0.20, 0.21 0.18, 0.18
Scheme 1. Schematic presentation of the reactions between CuX2 salts (X = NO3 and CF3SO3) and (a) 4,7-phen and (b) 1,7-phen. The numbering scheme of carbon atoms in
1,7-phen is in accordance with IUPAC recommendations for fused ring systems.
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atom of 4,7-phen was also previously noticed for copper(I) com-
plexes, e.g. [{Cu2(4,7-phen)(4,7-Hphen)2}Mo12AsO4]2.66H2O [36]
and [Cu(NCS)2(4,7-Hphen)]n [37], characterized by X-ray
crystallography.
The coordination geometry around Cu(II) in 2 is square pyrami-
dal (Figs. 1 and S1), as can be deduced from the trigonality index s
of 0.04/0.002 [38], s = (b  a)/60 where b = N1ACu1AN3/
O3ACu2AO4 = 171.05(12)/170.82(14) and a = O1ACu1AO2/
N5ACu2AN7 = 168.57(13)/170.17(13). The perfect square pyra-
midal and trigonal bipyramidal geometries result in s values of 0
and 1, respectively [38]. The Cu(II) ion is equatorially coordinated
by two nitrogen atoms of 4,7-phen and two oxygen atoms of water
molecules. The remaining coordination site at the axial position in
2 is occupied by a triﬂate oxygen atom. As a consequence of a
pseudo-Jahn–Teller distortion, the axial CuAO8/6A(triﬂate) bond
(2.383(3)/2.373(11) Å) is signiﬁcantly longer than the equatorial
CuAO(water) and CuAN(4,7-phen) bonds (Table 2). As can be seen
from Fig. 1, the coordinated triﬂate anion adopts a staggered
ethane-like conformation around the SAC bond.
The molecular structures of compounds 3a and 4 with the crys-
tallographic numbering scheme are shown in Fig. 2, while that of
3b is given in Supplementary Information (Fig. S2). The structures
of 3a and 3b have the same phenanthrolinium and nitrate parts,
however the angle between these two parts is different. Indeed,
the angle formed by the intersection of the two planes (the ﬁrst
one contains the phenanthrolinium, the second one the nitrate
ion, respectively, blue and red planes in Fig. 3.) in 3a and 3b
amounts to ca. 20 and 8, respectively (Fig. 3). This difference in
the nitrate position leads to a different motif in the packing that
be concluded that compounds 3a and 3b are conformational
polymorphs.
Contrary to our results, the reactions of copper(I) halide with
1,7-phen in acetonitrile led to the formation of polynuclear cop-
per(I) complexes, in which this ligand is monodentately coordi-
nated to the Cu(I) ion via the less sterically hindered N7 nitrogen,
as was shown by X-ray crystallography [39].
3.1.2. Spectroscopic characterization
The spectroscopic data for the copper(II) complexes 1 and 2 and
1,7-phenanthrolinium salts 3a/b and 4 are presented in the Exper-
imental section (vide supra).
Copper(II) complexes 1 and 2 exhibit a single broad and sym-
metric band in the expected region [40], which can be assigned
to the dz2, dxy, dxz, dyz? dx2y2 transitions with a dx2y2 ground state
[41]. The shape of the UV–Vis spectra and position of maximum
absorption of 1 and 2 are in accordance with those reported for
the other copper(II) complexes with aromatic N-heterocycles [22].
In compounds 3a/b and 4, the corresponding absorbance peak at
268.0 nm can be attributed to p? p* transitions in 1,7-Hphen+ [24].
The IR spectra of the products 1–4 display the bands due to the
coordinated and/or protonated N-heterocycle and the correspond-
ing anion X (X = NO3 and CF3SO3). A band originated from the
nitrate asymmetric stretching vibrations in the IR spectrum of cop-
per(II) complex 1 is split into four strong intensity bands, which is
an indication of the presence of coordinated nitrate which also par-
ticipates in the hydrogen bonding interactions and nitrate incorpo-
rated in the crystal lattice as counter-ion [42,43]. Similarly, the IR
t f 2 h i d t t t iﬂ t d di t d
Fig. 1. Molecular structures of copper(II) complexes 1 (#1: x + 2, y + 1, z + 1) and 2. Non-coordinating nitrates (1) are connected with the phenanthrolinium parts via
hydrogen bonds, while triﬂate counter-anion (2) is omitted for clarity. Only one of the two independent moieties of 2 is shown. Displacement ellipsoids are drawn at 50%
probability level and H atoms are represented by spheres of arbitrary size.
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with that of Cu(CF3SO3)2 salt, the band at 1289 cm1 can be attrib-
uted to the mas(SAO) of the CF3SO3 counter-anion, while those at
1240 and 1229 cm1 are due to the same vibrations of the mon-
odentately coordinated triﬂate [44–46]. Contrary to this, in the IR
spectrum of 3a/b, only one very strong band at 1384 cm1 due to
the mas(NO3) is observed, indicating that the nitrate solely acts as
counter-ion [42,43], while in that of 4, the band due to the mas(SO3)
is split into two bands (1289 and 1252 cm1) as a consequence of
its participation in the hydrogen bonding interactions [47].
The protonation of the N7 nitrogen atom in 1,7-phen in com-
pounds 3a/b and 4 is also evident from 1H NMR spectra; a broad
singlet at 3.80 and 4.12 ppm, respectively, was noted. Moreover,
the protonation process changes the electronic features of 1,7-
phen, resulting in the appearance of eight proton signals in the
spectra of 3a/b and 4, instead of ﬁve in that of 1,7-phen [24].
3.2. Antimicrobial and cytotoxic activity of the copper(II) complexes 1
and 2
Given the traditional antimicrobial properties shown by cop-
per-containing surfaces and complexes [11–21], the activity of
the newly synthesized copper(II) complexes 1 and 2, along with
CuX2 salts (X = NO3 and CF3SO3) used for their synthesis, were
evaluated against two Gram-positive (S. aureus and L. monocytoge-
nes) and two Gram-negative bacteria (P. aeruginosa and E. coli) as
well as the fungus C. albicans (Table 4). It was found previously that
4,7-phen did not exert signiﬁcant antimicrobial activity against the
investigated strains, yet had a slight cytotoxic effect on the MRC-5
cell line [25,26]. While CuX2 salts were not active against the
investigated strains at concentrations lower than 400 mM, 1 and
2 showed slightly better growth inhibiting activity, suggesting that
the antimicrobial effect of the complexes is multifactorial. The
complexes 1 and 2 exhibited comparable activity, with 1 being
slightly more active against the tested strains. The efﬁciency of
the complexes 1 and 2 was higher than that shown by copper(II)
complexes with aromatic N-heterocycles, pyrimidine, pyrazine,
quinazoline and phthalazine [22], but signiﬁcantly lower than
Table 2
Selected bond distances (Å) and valence angles () in copper(II) complexes 1 and 2.
1 2
Cu1AO1 1.992(2) Cu1AO1 1.960(3)
Cu1AO1i 1.992(2) Cu1AO2 1.941(3)
Cu1AN1i 2.007(2) Cu1AO8 2.383(3)
Cu1AN1 2.007(2) Cu1AN1 2.028(3)
Cu1AO2 2.446(2) Cu1AN3 2.021(3)
Cu1AO2i 2.446(2) Cu2AO3 1.935(3)
Cu2AO4 1.953(3)
Cu2AN5 2.027(3)
Cu2AN7 2.041(3)
Cu2AO6A 2.373(11)
O1ACu1AO1i 180.00(10) O1ACu1AO8 90.39(11)
O1ACu1AN1i 90.40(9) O1ACu1AN1 88.22(12)
O1iACu1AN1i 89.60(9) O1ACu1AN3 90.56(11)
O1ACu1AN1 89.60(9) O1ACu1AO2 168.57(13)
O1iACu1AN1 90.40(9) O2ACu1AO8 101.04(12)
N1iACu1AN1 180.0 O2ACu1AN1 89.23(12)
O1iACu1AO2 122.74(8) O2ACu1AN3 90.23(12)
O1ACu1AO2 57.26(8) N1ACu1AO8 101.78(11)
N1ACu1AO2 90.02(8) N3ACu1AO8 87.09(11)
N1iACu1AO2 89.98(9) N1ACu1AN3 171.05(12)
C1AN1ACu1 116.37(19) S2AO8ACu1 138.02(18)
C5AN1ACu1 125.32(18) C1AN1ACu1 113.3(2)
N3AO1ACu1 102.36(16) C5AN1ACu1 128.1(2)
N3AO2ACu1 82.49(16) C13AN3ACu1 116.6(2)
C17AN3ACu1 124.0(2)
O3ACu2AO4 170.82(14)
O3ACu2AN5 89.09(12)
O3ACu2AN7 90.11(11)
O3ACu2AO6A 103.1(3)
O4ACu2AN5 89.56(11)
O4ACu2AN7 89.67(11)
O4ACu2AO6A 85.9(3)
N5ACu2AN7 170.17(13)
N5ACu2AO6A 86.5(3)
N7ACu2AO6A 103.2(3)
S1AO6AACu2 137.9(6)
C25AN5ACu2 117.0(2)
C29AN5ACu2 122.5(2)
Symmetry code: (i) x + 2, y + 1,
z + 1
C37AN7ACu2 115.5(2)
C41AN7ACu2 125.2(2)
Table 3
Hydrogen bond parameters for 1–4.
DAH  A DAH (Å) H  A (Å) D  A (Å) DAH  A ()
1
N2AH2N. . .O4 0.88 1.95 2.825(3) 172.6
N2AH2N. . .O5i 0.88 2.36 2.971(4) 127.0
Symmetry code: (i) x + 2, y + 1, z + 1
2
O1AH1A. . .N6i 0.837(18) 1.938(19) 2.774(4) 178(5)
O1AH1B. . .O9ii 0.843(18) 1.864(19) 2.707(4) 178(4)
O2AH2A. . .O11iii 0.834(18) 1.926(19) 2.752(5) 171(4)
O2AH2B. . .N8 0.852(18) 1.87(2) 2.708(4) 169(5)
O3AH3A. . .O14 0.844(18) 1.93(2) 2.762(5) 168(5)
O3AH3A. . .O15A 0.844(18) 2.16(5) 2.748(15) 127(5)
O3AH3B. . .N4iii 0.853(18) 1.843(19) 2.696(4) 178(4)
O4AH4A. . .N2iv 0.844(18) 1.889(18) 2.730(4) 174(4)
O4AH4B. . .O7iv 0.845(18) 1.96(3) 2.736(7) 153(5)
Symmetry codes: (i) x, y  1, z + 1; (ii) x + 1, y, z + 1; (iii) x + 1, y + 1, z + 1; (iv) x + 1, y + 1, z
3a
N1AH1A. . .O1 0.98(4) 1.74(4) 2.724(5) 174(4)
N1AH1A. . .O2 0.98(4) 2.39(4) 3.075(5) 126(3)
3b
N1AH1A. . .O1 0.97(4) 1.70(4) 2.665(4) 179(4)
N1AH1A. . .O2 0.97(4) 2.47(4) 3.076(4) 120(3)
4
N1AH1A. . .O1i 0.96(4) 1.88(4) 2.838(4) 176(4)
Symmetry code: (i) x, y + 1, z + 1
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the antimicrobial activity of copper(II) complexes with antimicro-
bially active ligands, such as 3,4,7,8-tetramethyl-1,10-phenanthro-
line and 4,7-diphenyl-1,10-phenanthroline (MIC values are in the
range 2.7–90.3 mM) [48]. No signiﬁcant difference in the activity
against the bacterial strains and C. albicans was observed, being
in contrast with copper(II) complexes with 2-acetylpyridine- and
2-benzoylpyridine-derived hydrazones, which had slightly better
antifungal activity, although still quite high (MIC values are in
Copper-based complexes have previously been investigated as
anticancer agents on the assumption that essential metal ions
may be less toxic for normal cells in comparison to cancer cells
[23]. Nevertheless, copper can also be toxic due to its redox activity
and afﬁnity for binding sites that should be occupied by other
metal ions [23]. The investigated copper(II) complexes and starting
salts exhibited negative effects on the viability of the healthy
human lung ﬁbroblast cell line MRC-5, whereby complex 1
Fig. 2. Molecular structures of 3a and 4. Displacement ellipsoids are drawn at 50% probability level for 3 and 35% for 4 and H atoms are represented by spheres of arbitrary
size. Hydrogen bonds are drawn as dashed blue lines.
Fig. 3. Angle formed by the intersection of the two planes in 3a (a) and 3b (b). The ‘‘phenanthrolinium plane” is presented in blue (aligned with the viewing direction), and
the ‘‘nitrate plane” in red.
Table 4
Minimal inhibitory concentrations (MIC, mM) against a panel of microorganisms and antiproliferative activity (IC50, mM) of copper(II) complexes 1 and 2 in comparison to CuX2
salts (X = NO3 and CF3SO3).
Compound 1 2 Cu(NO3)23H2O Cu(CF3SO3)2
Staphylococcus aureus 200 400 >400 >400
Listeria monocytogenes 400 400 >400 >400
Pseudomonas aeruginosa 400 >400 >400 >400
Escherichia coli 400 400 >400 >400
Candida albicans 400 >400 >400 >400
MRC-5 (human lung ﬁbroblasts)a 100 ± 5 120 ± 10 300 ± 10 250 ± 10
a IC50 is deﬁned as the concentration inhibiting 50% of cell growth after 48 h treatment with the tested compounds.
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ing that some of the observed effects for 1 and 2 are due to the
presence of this ligand [25,26]. Recently, IC50 values in the range
24.0–289.0 mM were reported for copper(II) complexes with
pyrimidine, pyrazine, quinazoline and phthalazine on the MRC-5
cell line [22], being in accordance with the present ﬁndings. On
the other hand, copper(II) complexes, which belong to the Casio-
peínas family, [Cu(L-N,N0)(X-N,O)]NO3 and [Cu(L-N,N0)(Y-O,O0)]
NO3, where L represents 2,20-bipyridine, 1,10-phenanthroline or
their substituted derivatives, X is an essential amino acid or pep-
tide and Y is either acetylacetonate or salicylaldehydate, showed
signiﬁcant cytotoxicity as a consequence of their ability to interact
with DNA [50–56]. The same is true for the mononuclear copper(II)
complexes containing 2,20:60,200-terpyridine (terpy) and its 40-sub-
stituted derivatives [57–63].
4. Conclusions
We have demonstrated that 1,7- and 4,7-phenanthroline (1,7-
and 4,7-phen) differ greatly in their ability to coordinate Cu(II)
ion in reactions with CuX2 salts (X = NO3 and CF3SO3). Ligand
4,7-phen coordinates monodentately to Cu(II) ion yielding [Cu
(NO3)2(4,7-Hphen)2](NO3)2 (1) and [Cu(CF3SO3)(4,7-phen)2(H2O)2]
CF3SO3 (2) complexes, while with 1,7-phen only protonated 1,7-
phen salts with NO3 (3a/b) and CF3SO3 (4) counter-ions were
obtained. In complex 1, obtained from the reaction with Cu
(NO3)2, both coordinated 4,7-phen ligands have protonated N7
nitrogen atoms. However, in complex 2, resulting from the reaction
with Cu(CF3SO3)2, no protonation of nitrogen atoms in 4,7-phen
ligands occurred. In compounds 1,7-HphenNO3 (3a/b) and 1,7-
HphenCF3SO3 (4), N1 nitrogen atom of 1,7-phen which is not pro-
tonated is sterically hindered and consequently not convenient for
Cu(II) coordination. The antimicrobial and cytotoxic activities of 1
and 2 against the investigated microbial strains and normal human
ﬁbroblast cell line MRC-5, respectively, are moderate, with more
pronounced cytotoxic effects.
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